BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A.

华盛顿州博瑟尔，2023年12月6日（环球通讯社）--Cocrystal Pharma，Inc.（纳斯达克：COCP）（“Cocrystal”或“公司”）宣布，使用CC-42344（一种用于治疗大流行和季节性甲型流感的新型口服抗病毒抑制剂）进行2a期人类挑战临床试验的第一名患者取得了成就。

This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. “There is an urgent need for new oral antivirals targeting pandemic and seasonal influenza that address drug resistance.

这项随机，双盲，安慰剂对照研究将评估口服CC-42344治疗受试者甲型流感感染的安全性，耐受性，病毒和临床测量。“迫切需要针对大流行和季节性流感的新型口服抗病毒药物，以解决耐药性问题。

CC-42344 was discovered using our proprietary structure-based drug discovery platform technology to inhibit the viral replication process. The data from this proof-of-concept clinical study will further validate CC-42344’s novel mechanism of action,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO.

CC-42344是使用我们专有的基于结构的药物发现平台技术发现的，以抑制病毒复制过程。来自这项概念验证临床研究的数据将进一步验证CC-42344的新型作用机制，”共晶总裁兼联合首席执行官SamLee博士说。

“We expect to report topline data from this clinical trial in 2024.” “We are excited about the potential CC-42344 holds to create a paradigm shift in the treatment of one the world’s most common viral infections,” added James Martin, Cocrystal’s CFO and co-CEO. “Currently approved antiviral treatments for influenza are prone to viral resistance, increasing the need for improved influenza treatments for patients that also provide significant cost savings to the global healthcare system.” About CC-42344In late 2022 Cocrystal reported favorable safety and tolerability results in the single-ascending and multiple-ascending dose portions of the healthy volunteer Phase 1 trial conducted in Australia. Preclinical data showed that CC-42344 is highly active against seasonal and pandemic influenza A strains.

“我们预计将在2024年报告这项临床试验的主要数据。”“我们对CC-42344的潜在应用感到兴奋，它将在治疗世界上最常见的病毒感染之一方面产生范式转变，”Cocrystal的首席财务官兼联合首席执行官詹姆斯·马丁（JamesMartin）补充道。“目前批准的流感抗病毒治疗容易产生病毒耐药性，这增加了对患者改进流感治疗的需求，这也为全球医疗保健系统节省了大量成本。“关于2022年末的CC-42344，共晶公司报告称，在澳大利亚进行的健康志愿者1期试验中，单次递增和多次递增剂量部分具有良好的安全性和耐受性。临床前数据显示CC-42344对季节性和大流行性甲型流感病毒株具有高度活性。

In October 2023 Cocrystal re.

2023年10月，共晶re。